The HTAsiaLink Annual Conference for this year happened on 4 – 7 September, hosted by the Malaysia Health Technology Assessment Section (MaHTAS) under the Ministry of Health, Malaysia. Researchers from HITAP participated in the conference and presented their research projects thr

Coming to Thailand with utmost excitement in receiving first-hand mentorship from senior HTA researchers from Health Intervention and Technology Assessment Program (HITAP) was truly fulfilling. We were not only taught on enhancing our skills in performing economic evaluation and budget impact analys

Health service research (HSR) has changed the way healthcare is delivered to patients and its and quality. The research has continually generated results that, if translated into policy and clinical practices, can improve health outcomes, and provide better patient care and treatment. However, the t

In 2018, Kenya’s President committed to achieving Universal Health Coverage (UHC) by 2022. Subsequently, in June of the same year, the Cabinet Secretary for Health formed a Health Benefits Advisory Panel (HBAP) to develop a benefits package for the UHC program. Through past engagements between the K

During May 2010 to March 2011, a feasibility study of the community health initiative for MCH care was conducted in the Lewe, Yedarshey and Tatkone Townships by HITAP, the WHO and the MoH, Myanmar. The first study mission in May 2010 developed a protocol for the community health initiative whi

The value of a Quality-Adjusted Life Year (QALY) used to screen medicines for inclusion in the National List of Essential Medicines (NLEM) in 2013 was 160,000 baht per QALY. Any medicines that cost less than this amount is considered to be cost-effective. However, is this figure consistent with publ

What do you think about COVID-19 vaccination certificates for international travel? This survey on COVID-19 vaccination certificates is part of a regional research study from the COVID-19 vaccination policy research and decision-support initiative in Asia (CORESIA). We would like

Introduction: The development of new technology to treat patients with metastatic renal cell carcinoma has resulted in promising outcomes in terms of extending life and improving quality of life. In Thailand, where health resources are limited, an economic evaluation of such technology would provide useful information for pricing and reimbursement

This report summarises the discussion during a meeting held on 30th June 2022 to discuss lessons learned from the RECOVERY Trial and areas of potential collaboration to conduct clinical research in Thailand. This meeting was supported by the National Health Foundation (NHF), the Access and Delivery

A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand. Pattara Leelahavarong1,2, Usa Chaikledkaew1,2*, Suradej Hongeng3, Vijj Kasemsup4, Yoel Lubell1,5, Yot Teerawattananon1 1Health Intervention and Technolog